| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-624 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2002-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caf4030855f576a45182c4e18d7c9a86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d586c64559bc298554d459194fb6043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e866d895dbd60a3b423e20182047c7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_080ab27dbe374356a7724e7b5b0cd52c |
| publicationDate |
2003-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2461351-A1 |
| titleOfInvention |
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
| abstract |
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragmen ts of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells. |
| priorityDate |
2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |